Association between introduction of 13-valent pneumococcal conjugate vaccine and burden of hospitalized adult pneumococcal disease in South Korea – a population-based retrospective database study
Abstract
Background: Information on the burden of pneumococcal disease and its association with vaccination in South Korea remains limited. This study aims to examine the incidence rate, case fatality rate, healthcare resource utilization and costs of pneumococcal disease in adults before and after the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into South Korea’s childhood immunization program (CIP) in 2014.
Methods: Episodes of eligible adults aged at least 18 years hospitalized with invasive pneumococcal disease or pneumonia between 1 January 2010 and 31 December 2019 were extracted from South Korea’s National Health Information Database. The Korean version of the International Classification of Diseases codes were used for case identification. Study findings were compared between pre-CIP (2010–2013) and post-CIP (2015–2019) periods. Changes in the level and slope change of incidence rates in the post-CIP period were assessed with interrupted time series analyses and reported using incidence rate ratio (IRR). Healthcare resource utilization components consisted of length of hospitalization, and number of inpatient, outpatient and emergency department visits. Direct costs were calculated.
Results: There were a total of 1,682 invasive pneumococcal disease episodes and 8,635 pneumonia episodes included in this study. Overall incidence rates for invasive pneumococcal disease and pneumonia were 0.4 and 2.1 episodes per 100,000 person-years, respectively. For invasive pneumococcal disease, there were no significant changes in the level of incidence rate (IRR = 1.26; 95% confidence interval [CI]: [0.99, 1.59]) and slope of incidence rate (IRR = 0.97; 95% CI: [0.93, 1.01]) in the post-CIP period. For pneumonia, level of incidence rate was significantly higher in the post-CIP period than in the pre-CIP period (IRR = 1.92; 95% CI: [1.51, 2.42]), but no difference in slopes were observed between the two time periods (IRR = 1.02; 95% CI: [1.00, 1.04]). Case fatality rate was 14.9% for invasive pneumococcal disease and 3.0% for pneumonia. The average total costs per pneumonia episode was higher in the post-CIP period (4.1 vs. 3.1 million Korean Won). Disease burden was generally higher in patients ≥ 65 years.
Conclusions: Incidence of invasive pneumococcal disease remained stable while incidence and economic burden of pneumonia in adults had increased after PCV13 introduction into South Korea’s CIP. Use of PCV13 and factors such as increased surveillance may explain the observed results.
Related
- Antimicrobial resistance trends and lineage distribution among invasive pneumococcal disease isolates pre- and post-pneumococcal conjugate vaccine introduction, South Africa
- Pneumococcal nasopharyngeal carriage, serotype distribution, and vaccination status in hospitalized children in Latvia: A cross-sectional study during the post-PCV13, pre-PCV15/PCV20 transition period
- Association between anaemia, micronutrient status, and pneumococcal vaccine responses in young Kenyan children
- Association Between Pre-Existing Anti-Diphtheria Toxoid IgG and Immune Responses to a CRM₁₉₇-Conjugated 14-Valent Pneumococcal Conjugate Vaccine in Infants: A Post Hoc Analysis of a Multicenter Phase III Trial
- Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine in Reducing Mortality Among Older Adults: A Real-World Retrospective Cohort Study in Guangzhou, China.
BibTeX
@article{song2026association,
title = {{Association between introduction of 13-valent pneumococcal conjugate vaccine and burden of hospitalized adult pneumococcal disease in South Korea – a population-based retrospective database study}},
author = {Joon Young Song and Eun Hwa Choi and Young June Choe and See-Hwee Yeo and Dony Patel and Cindy Thiow Koon Lim and Young Eun Lee and Eriko Yamada and Isaya Sukarom},
journal = {BMC Public Health},
year = {2026},
month = oct,
doi = {10.1186/s12889-026-29058-6},
url = {https://link.springer.com/10.1186/s12889-026-29058-6},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Association between introduction of 13-valent pneumococcal conjugate vaccine and burden of hospitalized adult pneumococcal disease in South Korea – a population-based retrospective database study
AU - Joon Young Song
AU - Eun Hwa Choi
AU - Young June Choe
AU - See-Hwee Yeo
AU - Dony Patel
AU - Cindy Thiow Koon Lim
AU - Young Eun Lee
AU - Eriko Yamada
AU - Isaya Sukarom
PY - 2026
DA - 2026/10/03
JO - BMC Public Health
DO - 10.1186/s12889-026-29058-6
UR - https://link.springer.com/10.1186/s12889-026-29058-6
AB - Background: Information on the burden of pneumococcal disease and its association with vaccination in South Korea remains limited. This study aims to examine the incidence rate, case fatality rate, healthcare resource utilization and costs of pneumococcal disease in adults before and after the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) into South Korea’s childhood immunization program (CIP) in 2014. Methods: Episodes of eligible adults aged at least 18 years hospitalized with invasive pneumococcal disease or pneumonia between 1 January 2010 and 31 December 2019 were extracted from South Korea’s National Health Information Database. The Korean version of the International Classification of Diseases codes were used for case identification. Study findings were compared between pre-CIP (2010–2013) and post-CIP (2015–2019) periods. Changes in the level and slope change of incidence rates in the post-CIP period were assessed with interrupted time series analyses and reported using incidence rate ratio (IRR). Healthcare resource utilization components consisted of length of hospitalization, and number of inpatient, outpatient and emergency department visits. Direct costs were calculated. Results: There were a total of 1,682 invasive pneumococcal disease episodes and 8,635 pneumonia episodes included in this study. Overall incidence rates for invasive pneumococcal disease and pneumonia were 0.4 and 2.1 episodes per 100,000 person-years, respectively. For invasive pneumococcal disease, there were no significant changes in the level of incidence rate (IRR = 1.26; 95% confidence interval [CI]: [0.99, 1.59]) and slope of incidence rate (IRR = 0.97; 95% CI: [0.93, 1.01]) in the post-CIP period. For pneumonia, level of incidence rate was significantly higher in the post-CIP period than in the pre-CIP period (IRR = 1.92; 95% CI: [1.51, 2.42]), but no difference in slopes were observed between the two time periods (IRR = 1.02; 95% CI: [1.00, 1.04]). Case fatality rate was 14.9% for invasive pneumococcal disease and 3.0% for pneumonia. The average total costs per pneumonia episode was higher in the post-CIP period (4.1 vs. 3.1 million Korean Won). Disease burden was generally higher in patients ≥ 65 years. Conclusions: Incidence of invasive pneumococcal disease remained stable while incidence and economic burden of pneumonia in adults had increased after PCV13 introduction into South Korea’s CIP. Use of PCV13 and factors such as increased surveillance may explain the observed results.
SN - 1471-2458
ER -